B&K: Completes Full Enrollment for Phase II Trial of Diabetic Foot Ulcer Therapy Pro-101-2

Bulletin Express07-13

B&K Corporation Limited (B&K) disclosed that patient enrollment for the Phase II clinical trial of its recombinant human platelet-derived growth factor BB (rhPDGF-BB) gel, Pro-101-2, has been completed.

The randomized, double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of Pro-101-2 in treating diabetic foot ulcers and to collect key parameters for a planned Phase III trial.

Management highlighted the milestone as a significant step in the company’s diabetic foot ulcer research program.

In accordance with Rule 18A.05 of the Hong Kong Listing Rules, B&K emphasized that there is no assurance Pro-101-2 will ultimately obtain regulatory approval or reach the market. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1194702144?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-13 20:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194702144","market":"hk","top_or_hot":-1,"title":"B&K: Completes Full Enrollment for Phase II Trial of Diabetic Foot Ulcer Therapy Pro-101-2","media":"Bulletin Express","content":"<p>B&K Corporation Limited (B&K) disclosed that patient enrollment for the Phase II clinical trial of its recombinant human platelet-derived growth factor BB (rhPDGF-BB) gel, Pro-101-2, has been completed.</p>\n<p>The randomized, double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of Pro-101-2 in treating diabetic foot ulcers and to collect key parameters for a planned Phase III trial.</p>\n<p>Management highlighted the milestone as a significant step in the company’s diabetic foot ulcer research program.</p>\n<p>In accordance with Rule 18A.05 of the Hong Kong Listing Rules, B&K emphasized that there is no assurance Pro-101-2 will ultimately obtain regulatory approval or reach the market. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>B&K: Completes Full Enrollment for Phase II Trial of Diabetic Foot Ulcer Therapy Pro-101-2</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nB&K: Completes Full Enrollment for Phase II Trial of Diabetic Foot Ulcer Therapy Pro-101-2\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-13 20:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>B&K Corporation Limited (B&K) disclosed that patient enrollment for the Phase II clinical trial of its recombinant human platelet-derived growth factor BB (rhPDGF-BB) gel, Pro-101-2, has been completed.</p>\n<p>The randomized, double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of Pro-101-2 in treating diabetic foot ulcers and to collect key parameters for a planned Phase III trial.</p>\n<p>Management highlighted the milestone as a significant step in the company’s diabetic foot ulcer research program.</p>\n<p>In accordance with Rule 18A.05 of the Hong Kong Listing Rules, B&K emphasized that there is no assurance Pro-101-2 will ultimately obtain regulatory approval or reach the market. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02396","symbol_name":"华芢生物-B","start_time":0,"source_url":"","article_id":"1194702144","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194702144","pubTimestamp":1783945239,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"B&K Corporation Limited (B&K) disclosed that patient enrollment for the Phase II clinical trial of its recombinant human platelet-derived growth factor BB (rhPDGF-BB) gel, Pro-101-2, has been...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02396":"华芢生物-B"},"translate_title":"B&K：完成糖尿病足溃疡治疗Pro-101-2 II期试验的全部入组","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02396":1},"content_text":"B&K Corporation Limited (B&K) disclosed that patient enrollment for the Phase II clinical trial of its recombinant human platelet-derived growth factor BB (rhPDGF-BB) gel, Pro-101-2, has been completed.\nThe randomized, double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of Pro-101-2 in treating diabetic foot ulcers and to collect key parameters for a planned Phase III trial.\nManagement highlighted the milestone as a significant step in the company’s diabetic foot ulcer research program.\nIn accordance with Rule 18A.05 of the Hong Kong Listing Rules, B&K emphasized that there is no assurance Pro-101-2 will ultimately obtain regulatory approval or reach the market. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1194702144","isCrawlerRequest":true}